Connect Biopharma Holdings (CNTB) Amortizatization of Intangibles (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted Amortizatization of Intangibles of $7000.0 for Q1 2026, down 89.55% sequentially from $67000.0 in Q4 2025, and down 97.19% YoY from $249000.0 in Q1 2025.
Connect Biopharma Holdings (CNTB) Amortizatization of Intangibles (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has reported Amortizatization of Intangibles for 3 years, with the latest figure at $7000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 97.19% year-over-year to $7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $531000.0 (up 87.63% YoY) and the FY2025 annual result came in at $773000.0, up 528.46% from the prior year.
- Amortizatization of Intangibles fell to $7000.0 in Q1 2026 per CNTB's latest filing, from $67000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $288000.0 in Q2 2025 and troughed at $7000.0 in Q1 2026.
- A 3-year average of $112875.0 and a median of $78000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2025 and 2026: Amortizatization of Intangibles jumped 2780.0% in 2025, then plunged 97.19% in 2026.
- Over 3 years, Amortizatization of Intangibles stood at $24000.0 in 2024, then jumped by 179.17% to $67000.0 in 2025, then sank by 89.55% to $7000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $7000.0, $67000.0, and $169000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Connect Biopharma Holdings | 148.41 Mn | 148.41 Mn | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,000.00 |
| Jun 30, 2026 | 3,000.00 |
| Mar 31, 2026 | 7,000.00 |
| Mar 31, 2026 | 7,000.00 |
| Dec 31, 2025 | 67,000.00 |
| Dec 31, 2025 | 67,000.00 |
| Sep 30, 2025 | 169,000.00 |
| Sep 30, 2025 | 169,000.00 |
| Jun 30, 2025 | 288,000.00 |
| Jun 30, 2025 | 288,000.00 |
| Mar 31, 2025 | 249,000.00 |
| Mar 31, 2025 | 249,000.00 |
| Dec 31, 2024 | 24,000.00 |
| Dec 31, 2024 | 24,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Mar 31, 2024 | 89,000.00 |
| Mar 31, 2024 | 89,000.00 |